Degenerative OsteoarthritisPhase 2NCT05276011
A Study to Determine the Safety and Efficacy of TG-C in Subjects With Symptomatic Early Hip Osteoarthritis
A Phase 2 study testing TG-C in people with Degenerative Osteoarthritis, run by Kolon TissueGene, Inc..
Trial summary
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Determine the Efficacy, Safety, and Dosing of TG-C in Adult Subjects with Symptomatic Early Hip Osteoarthritis. TG-C will be administered to the target hip by a single ultrasound (or fluoroscopy)-guided, intra-articular injection with image capture… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Degenerative Osteoarthritis
- What is being tested?
- TG-C
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 255 participants
- Where
- No sites listed yet
- Study dates
- Oct 2027to Oct 2028
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18 to 80 years old
- The subject has a diagnosis of Grade ≤2 primary OA of the target hip
- Pain ≥ 40 on VAS scale
- The subject has groin pain that is elicited by hip rotation on physical examination
- No history of significant organ system disorders.
- Body mass index (BMI) <40 kg/m2
Show all 9Show fewer
- Systolic blood pressure of 100 to 160 mmHg and diastolic blood pressure of 60 to 90 mmHg.
- Using birth control
- Written informed consent
Who cannot join
- The subject exhibits severe symptoms in the target hip that result in difficulty or an inability to walk.
- The subject has severe hip OA ipsilateral to the target hip.
- Previous cartilage transplantation procedure to the injured cartilage surface.
- Major injury to the target hip within 12 months of screening.
- Active dermal ulcer or infection in the proximity of the target hip within 1 month before screening.
- The subject has had surgery on the target hip within the last 6 months.
Show all 24Show fewer
- Total hip replacement surgery or other surgery on the target hip in the next 12 months.
- MRI indicates bone marrow infiltration, fracture, osteonecrosis/bone infarct, osteochondritis dissecans, tumor, moderate to severe dysplasia, avascular necrosis, post-traumatic arthritis, transient osteoporosis, slipped-cap femoral epiphysis, juvenile idiopathic arthritis, or axial juvenile spondyloarthritis.
- Hip conditions including but not limited to any autoimmune or infectious cause for arthritis; metabolic joint disease; neuropathic disorders, groin pain from non-orthopedic sources, or tumors, congestive heart failure, or chronic kidney disease.
- Uncontrolled diabetes based on a hemoglobin A1c (HbA1c) value >8% at the screening Visit.
- Increased risk for post-procedure bleeding or post-procedure infection.
- Ongoing infectious disease, including, but not limited to, HIV, hepatitis C, or current or prior hepatitis B.
- Cognitive impairment that would limit his/her ability to provide informed consent or to complete assessments and questionnaires.
- 1 year history of drug or alcohol abuse.
- Contraindication to or cannot undergo MRI.
- Active malignancy within the last 5 years.
- Pregnant or is lactating.
- Taken steroidal or NSAIDs within 14 days before the Baseline Visit
- Using topical analgesics on the target hip
- Receiving chronic narcotic treatment at screening.
- Received any injection to the target hip within the 3 months before the Baseline Visit.
- Taking antiplatelet or anticoagulants.
- Participated in an investigational study within 13 weeks before the Screening Visit or in the next 25 months.
- Unable to comply with the requisite study follow-up and all of the follow-up office visits.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Determine the Efficacy, Safety, and Dosing of TG-C in Adult Subjects With Symptomatic Early Hip Osteoarthritis
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Determine the Efficacy, Safety, and Dosing of TG-C in Adult Subjects with Symptomatic Early Hip Osteoarthritis. TG-C will be administered to the target hip by a single ultrasound (or fluoroscopy)-guided, intra-articular injection with image capture showing correct injection of study drug into the femoroacetabular joint. Patients will be followed for 12 months for safety and efficacy.
Read the detailed description
This protocol is designed to assess the safety and efficacy of TG-C in treating symptoms of osteoarthritis of the hip and determining disease modifying effects of TG-C. TG-C will be compared to normal saline as a control. Safety will be evaluated by observation of the injection site for irritation or other effects, the incidence and severity of adverse events, and changes in physical examination findings, radiographic criteria, and laboratory tests. Patients will be followed for 12 months for both safety and efficacy.
- Conditions
- Degenerative Osteoarthritis
- Being tested
- TG-C, Placebo Control
- Keywords
- hip
- Medical subject headings
- Joint Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TG-CBiological
Also called TissueGene-C
2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
Placebo ControlBiological
Also called Normal Saline
2 mL normal saline injection
| Study group | Role | What they receive |
|---|---|---|
| Active Treatment (TG-C) | Active comparator | TG-C at 1.0 x 10e7 cells per single 2 mL intraarticular injection Receives: Biological: TG-C |
| Active Treatment 2 (TG-C) | Active comparator | TG-C at 3.0 x 10e6 cells per single 2 mL intraarticular injection Receives: Biological: TG-C |
| Placebo Control (Normal Saline) | Placebo comparator | Normal saline, single 2 mL intraarticular injection Receives: Biological: Placebo Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Hip Pain as Assessed by VAS
Assessment of change from baseline in target hip pain using the Visual Analog Scale (VAS). The VAS is a method for the assessment of the intensity of pain. The VAS is a horizontal line, 100 mm in length and anchored by word descriptors at each end (no pain, very severe pain). The patient marks on the line at the point that represents their current state. The VAS score is determined by measuring in millimeters from the left hand end to the point of the mark. The score ranges from "0" or no pain to "100" very severe pain.
Measured: Baseline to Month 12
Secondary outcomes (5)
Hip Disability and Osteoarthritis Outcome Score (HOOS)
The HOOS questionnaire was built upon the Western Ontario and MacMaster Universities Osteoarthritis Index (WOMAC®). Questions from the WOMAC® were used as the basis for the survey, and 2 dimensions were added: sport and recreation and hip-related quality of life. The HOOS is composed of 40 questions in 5 subscales: Pain (10 items), Symptoms (5 items), Activity of Daily Living (17 items), Sport and Recreation Function (4 items), and Hip-Related Quality of Life (4 items). A total score, ranging from 0 to 100 is calculated. Higher scores represent better functioning.
Measured: Baseline to Month 12
Timed Up and Go Test (TUG)
The TUG test is used to determine the time needed to progress from sitting to standing and walking. In addition, the test helps to evaluate the probability for falls. The individual starts in a seated position in a chair with armrests and, upon command, stands up, walks 3 meters, turns around, walks back to the chair, and sits down. The time stops when the subject is seated. The use of walking aids should be recorded and kept consistent between tests.
Measured: Baseline to Months 1, 3, 6, 9, and 12
UCLA Activity Score
The UCLA Activity Score includes 10 statements that cover the range of activity states from being "wholly inactive, dependent on others, and cannot leave residence" to "regularly participate in impact sports." The respondents are instructed to select one statement that is most representative of their current activity. Lower scores on the scale reflect a low level of activity and higher scores reflect more activity.
Measured: Baseline to Months 1, 3, 6, 9, and 12
Joint Space Width (JSW) on standing X-ray
To evaluate the effects of 2 dose levels of TG-C on the structural features of the hip joint
Measured: Baseline to Month 12
WOMAC® (Western Ontario and McMaster Universities Osteoarthritis Index) total score
To evaluate the effects of 2 dose levels of TG-C on symptoms of OA of the hip. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.
Measured: Baseline to Month 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2022
- Study startOct 2027 (estimated)
- Primary completionOct 2028 (estimated)
- Study completionOct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Degenerative OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 255 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kolon TissueGene, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Moon Jong Noh, PhD, Study chair, Kolon TissueGene, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05276011
- Sponsor's protocol ID
- TGC-OAH-201
- Status last verified
- Aug 2026
- First submitted
- 2 Mar 2022
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No